C07K 14/70582
Cd71
Official title: {cd71}
C07K14/70582 (Cd71) appears on 36 US grants and 53 published applications in this corpus.
Search patents in C07K- Granted patents
- 36
- Published applications
- 53
- Assignees
- 35
- Inventors
- 142
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 3 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 1 |
| 2002 | 0 | 0 |
| 2003 | 1 | 1 |
| 2004 | 0 | 2 |
| 2005 | 1 | 2 |
| 2006 | 1 | 2 |
| 2007 | 2 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 0 |
| 2010 | 2 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 2 |
| 2017 | 0 | 2 |
| 2018 | 1 | 3 |
| 2019 | 3 | 5 |
| 2020 | 0 | 5 |
| 2021 | 0 | 1 |
| 2022 | 3 | 3 |
| 2023 | 5 | 3 |
| 2024 | 4 | 9 |
| 2025 | 0 | 9 |
| 2026 | 3 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Genetically modified non-human animal with human or chimeric TFR122 Sep 2026US 12,740,550 B2Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Compounds and methods for reducing PLN expression22 Sep 2026US 12,742,170 B2Ionis Pharmaceuticals, Inc.
- CD71 binding fibronectin type III domains31 Mar 2026US 12,589,159 B2ARO Biotherapeutics Company
- Methods of engineering transferrin receptor binding polypeptides10 Dec 2024US 12,162,948 B2Denali Therapeutics Inc.
- CD71 binding fibronectin type III domains16 Jul 2024US 12,037,379 B2ARO Biotherapeutics Company
- Cd71 binding fibronectin type iii domains6 Aug 2026US 2026/0224718 A1ARO Biotherapeutics Company
- Anti-tfr1 single-domain antibody and use thereof30 Jul 2026US 2026/0217847 A1Nanjing Regenecore Biotech Co., Ltd.
- Transferrin receptor-binding domains and proteins comprising the same30 Oct 2025US 2025/0333528 A1Denali Therapeutics Inc.
- Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof23 Oct 2025US 2025/0326866 A1Blaze Bioscience, Inc.
- Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host16 Oct 2025US 2025/0319173 A1
Most cited
By later US patents
- Method for detecting a mammal's prior exposure to radiation or radiomimetic chemicals31US 5,691,157 AThe Research Foundation of State University of New York · 1997
- Compositions comprising the Tbp2 subunit of the transferrin receptor of Neisseria meningitidis19US 6,028,049 APasteur Merieux Serums et Vaccins · 2000
- In vitro production of red blood cells with proteins comprising sortase recognition motifs17US 10,471,099 B2Whitehead Institute for Biomedical Research · 2019
- 1gG /transferrin receptor fusion protein13US 6,225,448 B1Neurotech S.A. · 2001
- Engineered polypeptides11US 10,457,717 B2Denali Therapeutics Inc. · 2019